Use of a probioitic to decrease enteric hyperoxaluria  by Lieske, John C. et al.
Kidney International, Vol. 68 (2005), pp. 1244–1249
Use of a probioitic to decrease enteric hyperoxaluria
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Use of a probioitic to decrease enteric hyperoxaluria.
Background. Patients with inflammatory bowel disease have
a 10- to 100-fold increased risk of nephrolithiasis, with enteric
hyperoxaluria being the major risk factor for these and other
patients with fat malabsorptive states. Endogenous components
of the intestinal microflora can potentially limit dietary oxalate
absorption.
Methods. Ten patients were studied with chronic fat malab-
sorption, calcium oxalate stones, and hyperoxaluria thought to
be caused by jejunoileal bypass (1) and Roux-en-Y gastric by-
pass surgery for obesity (4), dumping syndrome secondary to
gastrectomy (2), celiac sprue (1), chronic pancreatitis (1), and
ulcerative colitis in remission (1). For 3 months, patients re-
ceived increasing doses of a lactic acid bacteria mixture (Ox-
adrop, VSL Pharmaceuticals), followed by a washout month.
Twenty-four–hour urine collections were performed at baseline
and after each month.
Results. Mean urinary oxalate excretion fell by 19% after 1
month (1 dose per day, P < 0.05), and oxalate excretion re-
mained reduced by 24% during the second month (2 doses per
day, P < 0.05). During the third month on 3 doses per day ox-
alate excretion increased slightly, so that the mean was close to
the baseline established off treatment. Urinary oxalate again
fell 20% from baseline during the washout period. Calcium ox-
alate supersaturation was reduced while on Oxadrop, largely
due to the decrease in oxalate excretion, although mean changes
did not reach statistical significance.
Conclusion. Manipulation of gastrointestinal (GI) flora can
influence urinary oxalate excretion to reduce urinary supersat-
uration levels. These changes could have a salutary effect on
stone formation rates. Further studies will be needed to estab-
lish the optimal dosing regimen.
Patients with inflammatory bowel disease have a risk
of nephrolithiasis that is 10 to 100 times that of the nor-
mal population, ranging from 1% to 25% [1]. Enteric
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hyperoxaluria has also been documented in other mal-
absorptive states, including after jejunoileal bypass for
obesity [2–4], after gastric ulcer surgery [3], and in the
setting of chronic mesenteric ischemia [3]. Patients often
have multiple stones, and nephrolithiasis is more com-
monly observed with ileocolonic disease (9–17%) com-
pared to ileal (6–8%) or colonic disease (3–5%) alone.
Renal stones are primarily composed of calcium oxalate
when the ileum is involved (e.g., ileocolonic Crohns dis-
ease), and uric acid when patients have copious diarrhea
or small bowel ostomies [1]. Contributing factors include
a low urinary citrate concentration, decreased urine vol-
umes, and a low urinary pH, all due to diarrhea and con-
sequent loss of fluid and bicarbonate in the stool. In ad-
dition, when the colon is intact, the percentage of oxalate
absorbed from the gut and, hence, the absolute amount
excreted in urine can be markedly increased [5], and in
general, the degree of hyperoxaluria correlates with steat-
orrhea [6].
Unfortunately, few satisfactory treatments for enteric
hyperoxaluria are available. Typical strategies include di-
etary restriction of oxalate to limit its delivery to the
colon, low fat diets to limit malabsorption and distal
colonic effects of fatty acids and bile acids [7, 8], oral cal-
cium to bind oxalate [2], and bile acid sequestrants like
cholestyramine [6, 7]. Dietary restriction of oxalate is not
always entirely effective because many patients cannot
readily identify causative dietary constituents [9]. In its
entirety, such a regimen is quite arduous and, even if com-
pliance is achieved, not always effective.
Investigators have previously demonstrated that com-
ponents of the endogenous digestive microflora can uti-
lize oxalate, potentially limiting its absorption from the
intestinal lumen [10]. A recent preliminary study found
that a preparation of lactic acid bacteria degraded ox-
alate in vitro and reduced urinary oxalate excretion when
given by mouth [11]. Therefore, the current study was
performed to determine if that same preparation (Ox-
adrop) can reduce urinary oxalate excretion in patients
with enteric hyperoxaluria, and if so, determine the min-
imal effective dose.
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METHODS
Oxadrop
Lactic acid bacteria are normal intestinal commen-
sals, and are ubiquitous in fermented and nonfermented
foods. The Food and Drug Administration (FDA) clas-
sifies them as “generally regarded as safe” (GRAS) and
permits them as food additives (FDA). In clinical trials
performed with Oxadrop [11], or the very similar prepa-
ration VSL#3 [12], there have been no adverse events
noted, and no case of clinical infection has been traced
to ingested probiotic lactic acid bacteria in a normal host
[13], although caution may be required for immunocom-
promised hosts [14]. Each gram of the mix (Oxadrop)
contains 2 × 1011 bacteria (Lactobacillus acidophilus, L.
brevis, Streptococcus thermophilus, and Bifidobacterium
infantis). The different strains are mixed in a 1:1:4:4 ratio
and prepared as a granulate. The organisms were cho-
sen based on their ability to degrade oxalate in vitro, and
Oxadrop is slightly different than the more widely stud-
ied VSL#3 [12], which contains 3 of the above 4 bacterial
species with the exception of L. brevis, as well as 3 other
species of Lactobacillus, and 2 other species of bifidobac-
teria.
Patient population
Patients with nephrolithiasis, clinical signs of fat mal-
absorption, and apparent enteric hyperoxaluria were re-
cruited for study from the Mayo Renal Stone Clinic. Men
and women age 18 or greater with the presence of hy-
peroxaluria (>0.5 mmol/L/day; >45 mg/day) and a gas-
trointestinal disorder associated with fat malabsorption
were eligible. Clinical malabsorptive syndromes consid-
ered included inflammatory bowel disease in remission,
celiac sprue, gastrointestinal resection resulting in short
bowel syndrome (e.g., jejunoileal or gastric bypass for
obesity; antrectomy, vagotomy, and pyloroplasty for gas-
tric ulcers), or chronic pancreatitis. Stone history was con-
firmed by the presence of radiopaque stones on x-ray, or
a history consistent with passage of a stone, stone surgery,
or ESWL in the last 2 years. Stone composition was con-
firmed either by stone analysis demonstrating more than
50% calcium oxalate, or by radiographic demonstration
of a calcific renal stone in the presence of hyperoxaluria.
Patients with immunosuppression (receiving chemother-
apy, known HIV infection, using oral prednisone or other
immunosuppressants) were not eligible. Patients com-
pleting a course of oral or parenteral antibiotics less than
2 weeks before initiation of the study were not eligible,
and patients who required a course of antibiotics during
the period of preparation administration were withdrawn
from the study and excluded from the final analysis.
Patients were maintained on previous doses of oxalate
binders (e.g., calcium), diet prescriptions (e.g., low ox-
alate diet), or other stone prevention treatments (e.g.,
citrate). While the diet was not specifically controlled,
patients were asked to maintain a similar diet during all
2-day urine collections. After informed consent was ob-
tained, 2 baseline 24-hour urines were collected on con-
secutive days. Patients then began taking 1 packet (4 g) of
the study preparation Oxadrop daily. The preparation
was mixed in a glass of cold beverage including water, or-
ange juice, or tea. It was not to be mixed with milk which
could serve as a substrate for growth. The dose was taken
1 to 2 hours after dinner, or the major meal of the day.
At the end of the 4-week period of drug administration, 2
repeat 24-hour urines were collected (days 27–28). Then
the dose of Oxadrop was increased to 2 packets daily,
taken together 1 to 2 hours after dinner, or the major
meal of the day. At the end of an additional 4 weeks
(week 8), 2 repeat 24-hour urines were collected (days
55–56). Finally, the dose of Oxadrop was increased to
3 packets a day (as a single dose 1–2 hours after dinner,
or the major meal of the day) for 4 more weeks. At the
end of this period (week 12), 2 more 24-hour urines were
collected (days 83–84). Two final urine collections were
done 4 weeks later off the preparation.
Urine chemistries
Twenty-four–hour urinary concentrations of oxalate,
calcium, and other determinants of supersaturation were
mailed to Litholink Corporation (Chicago, IL, USA)
for analysis. Supersaturations were calculated using the
EQUIL2 program [15].
Statistics
Group means and distributions at each time period
were compared by paired t test using JMP software (SAS
Institute, Inc., Cary, NC, USA). P values < 0.05 were ac-
cepted as significant.
RESULTS
Causes of enteric hyperoxaluria were bypass surgery
for obesity [jejunoileal bypass (1) and Roux-en-Y gas-
tric bypass surgery (4)], dumping syndrome secondary to
gastrectomy (2), celiac sprue (1), chronic pancreatitis (1),
and ulcerative colitis in remission (1). Although both men
and women were eligible and recruited, only a group of
men ages 51 to 69 elected to enroll in this pilot study.
In 7 of the 10 patients urine oxalate excretion fell or
remained stable after 1 month of treatment using 1 dose
of Oxadrop per day (mean decrease 19%) (Table 1 and
Fig. 1). This drop remained relatively stable during the
second month on 2 doses per day (mean decrease 24%).
During the third month on 3 doses per day, urine ox-
alate increased in 4 of 10 patients so that the mean was
then 2% below baseline. Interestingly, oxalate excretion
once again slightly fell after the 1-month washout period
1246 Lieske et al: Probiotics for enteric hyperoxaluria
Table 1. Summary of mean urinary changes for 10 enteric hyperoxaluric patients before, during and after one month on 3 doses of Oxadrop
Month 1 Month 2 Month 3
Urine parameter Baseline (1 packet QD) (2 packets QD) (3 packets QD) Washout
Oxalate mg 91 (48) 74 (30)a 69 (36)a 89 (51) 73 (41)a
Oxalate/creatinine ratio 0.049 (0.021) 0.040 (0.015)a 0.039 (0.019)a 0.044 (0.018) 0.038 (0.016)
ss CaOx 8.14 (4.63) 7.97 (3.90) 7.02 (3.19)b 7.60 (3.34) 7.90 (3.24)
Volume L 2.22 (0.61) 2.07 (0.84) 1.87 (0.61)a 2.00 (0.64) 1.93 (0.68)b
Calcium mg 154 (91) 143 (49) 129 (82)b 138 (85) 152 (81)
Citrate mg 549 (387) 512 (374) 557 (361) 543 (338) 521 (401)
pH 6.24 (0.48) 5.96 (0.46)a 5.99 (0.54)a 5.85 (0.43)a 5.85 (0.37)a
Urate g 0.67 (0.28) 0.58 (0.19)a 0.63 (0.27) 0.64 (0.26) 0.69 (0.26)
Sodium mEq 244 (84) 212 (54)a 191 (59) a 222 (68) 211 (84)
Potassium mEq 86 (34) 76 (37)a 71 (27)a 79 (27) 68 (26)a
Magnesium mg 119 (49) 122 (39) 104 (40)a 123 (37) 106 (52)
Sulfate mEq 42 (15) 42 (12) 44 (11) 43 (11) 43 (12)
Ammonium mmol/L 57 (34) 69 (48) 58 (41) 66 (44) 63 (31)
Phosphorous g 1.09 (0.38) 0.99 (0.35) 1.03 (0.30) 1.22 (0.45) 1.03 (0.33)
ss CaP 0.75 (0.48) 0.68 (0.72) 0.60 (0.48) 057 (0.52) 0.61 (0.53)
ss Urate 0.56 (0.49) 0.91 (0.80) 1.07 (0.96) 1.12 (0.886) 1.17 (0.93)
Creatinine mg 1883 (498) 1876 (481) 1804 (438) 1992 (497) 1883 (477)
Values are mean (SE).
aP < 0.05.
bP < 0.10 vs. baseline.
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Fig. 1. Changes in urinary oxalate excretion
on Oxadrop. Ten patients with enteric hy-
peroxaluria were treated with Oxadrop in
increasing doses for 3 months preceded by
a baseline value (month 0) and followed by
a washout period (month 4). Each patient is
represented by an individual line in (A) with
mean values in (B). Oxalate excretion fell in
7 of 10 patients after the first month on 1 dose
per day (mean decrease 19% from baseline),
was reduced in 8 of 10 after 2 months on 2
doses per day (mean decrease 24% from base-
line), but increased toward baseline levels in
4 patients after month 3 on 3 doses per day
(mean decrease 2% from baseline). During
the washout phase oxalate fell slightly in 5 of
10 patients for a mean decrease of 20% from
baseline. Each point in (A) is the average of
2 consecutive 24-hour urine collections. Each
value in (B) is mean ± 95th percentile, ∗P <
0.05 vs. baseline (month 0).
so that the mean was 20% less than during the baseline.
Results expressed as oxalate:creatinine ratio, to correct
for variations in urine collection, were largely similar, al-
though the percentage decrease at month 3 was slightly
more (Fig. 2). Urinary calcium oxalate supersaturation
fell throughout the study, mostly due to changes in ox-
alate excretion, although results did not reach statistical
significance (Fig. 3), perhaps because a slight fall in urine
volume partially offset the fall in urine oxalate during
months 1 and 2 (Table 1). Uric acid supersaturation rose
slightly on the higher doses of Oxadrop due to a slight
fall in urinary pH, but was still below the reference mean
for normals in our lab (2.04), suggesting the risk for uric
acid stones was not significantly increased.
Adverse events
No adverse events were noted in patients while on the
study preparation. Two subjects withdrew within the first
month of the protocol; one that received a course of an-
tibiotics to treat a respiratory syndrome, and the other
due to poor compliance with dosing and follow-up test-
ing. Their data were not included.
DISCUSSION
These results suggest that manipulation of gastroin-
testinal flora in patients with fat malabsorption using
Oxadrop can influence oxalate absorption and, hence,
urinary oxalate excretion, and reduce urinary supersatu-
ration levels. Because stone formation parallels supersat-
uration, we predict these changes would have a salutary
effect on stone formation rates. The results also suggest
that there is an optimal dose, and that it might be possible
to give too much of the agent. Therefore, careful dosing
studies will be required in the future.
In patients with gastrointestinal diseases associated
with fat malabsorption, 2 mechanisms of increased
colonic oxalate uptake are commonly purported. (1) Bile
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Fig. 2. Changes in urinary oxalate: creatinine
ratio on Oxadrop. Ten patients with enteric
hyperoxaluria were treated with Oxadrop
in increasing doses for 3 months preceded by
a baseline value (month 0) and followed by
a washout period (month 4). Each patient is
represented by an individual line in (A) with
mean values in (B). Oxalate-creatinine ratio
fell in 7 of 10 patients in the first month on 1
dose per day (mean decrease 18% from base-
line), was reduced in 8 of 10 after month 2
on 2 doses per day (mean decrease 21% from
baseline), and increased toward baseline lev-
els in 5 patients after month 3 on 3 doses per
day (mean decrease 10% from baseline). Dur-
ing the washout phase oxalate-creatinine ratio
again fell slightly in 6 of 10 patients for a mean
decrease of 22% from baseline. Each point in
(A) is the average of 2 consecutive 24-hour
urine collections. Each value in (B) is mean ±
95th percentile, ∗P < 0.05 vs. baseline (month
0).
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Fig. 3. Changes in urinary calcium oxalate
supersaturation on Oxadrop. Ten patients
with enteric hyperoxaluria were treated with
Oxadrop in increasing doses for 3 months
preceded by a baseline value (month 0) and
followed by a washout period (month 4). Each
patient is represented by an individual line
in (A) with mean values in (B). Overall cal-
cium oxalate supersaturation was relatively
flat in many patients, but the mean for the
group did fall slightly, especially at month 2
(decreased 14% from baseline). Each value
in (B) is mean ± 95th percentile, #P < 0.10 vs.
baseline (month 0).
salt malabsorption due to the ileal disease resulting in fat
malabsorption. The increased colonic fats then bind to
free calcium, increasing unbound oxalate that is able to
cross the colonic mucosa. (2) Colonic permeability is in-
creased by malabsorbed fatty acids and bile acids, perhaps
induced by changes in epithelial tight junctions, allowing
oxalate to pass from the intestine into the blood stream.
Unabsorbed bile acids may also exert damaging effects
on intestinal oxalate-metabolizing bacteria, thereby in-
creasing oxalate available for absorption [10]. Regardless
of the mechanism, in malabsorptive states the percentage
of oxalate absorbed from the gut and excreted in urine
can be markedly increased, and hyperoxaluria correlates
with steatorrhea [6]. Additional factors that contribute to
stone formation include a low urinary pH, low urinary cit-
rate concentration, and decreased urine volumes, due to
the diarrhea and consequent loss of fluid and bicarbonate
in the stool.
The relative importance of hyperoxaluria as a cause of
idiopathic calcium oxalate stone disease remains contro-
versial, especially in relationship to hypercalciuria. How-
ever, many studies have identified mild hyperoxaluria in
a subset of these patients [16]. In addition, it has been
speculated that the normal urinary range, small changes
in oxalate concentration could influence supersaturation
with respect to calcium oxalate far more than changes in
calcium concentrations [16], although recent studies sug-
gest that both ions are equally important determinants
[17]. Further, it is relatively easy to initiate calcium ox-
alate crystallization by addition of oxalate to urine in vitro
[18]; therefore, relatively modest effects on urinary ox-
alate excretion, if sustained, could have more significant
clinical effects on crystal growth and stone formation rate.
For patients with idiopathic calcium oxalate stones
and mild hyperoxaluria, the mechanisms that mediate in-
creased oxalate excretion are poorly understood. On a
typical Western diet, only about 10% of ingested oxalate
is typically absorbed, and this is thought to constitute
about one third of the total urinary oxalate, the other two
thirds being synthesized by the liver [19]. However, the
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contribution of dietary oxalate to urinary oxalate could
vary widely among individuals because dietary oxalate
can vary from 70 to 930 mg/day on a typical Western
diet, to as much as 2000 mg while ingesting certain highly
vegetarian diets [20]. Factors known to influence the per-
centage of this dietary oxalate that is absorbed include
the availability of free calcium and magnesium ions that
can complex with oxalate and decrease its rate of ab-
sorption, and the presence of free fats in the distal colon,
which can form soaps with calcium and thereby increase
concentration of free oxalate [20]. Recent [21, 22] and
older [23–25] studies also support the hypothesis that in-
creased gastrointestinal absorption of oxalate due to fac-
tors independent of diet could mediate hyperoxaluria in
a subgroup of calcium oxalate stone formers. There is ev-
idence that specific energy-dependent transporters might
mediate both net oxalate absorption, as well as oxalate
excretion [26]. The latter might be particularly critical in
eliminating excess oxalate when renal function is reduced
[27].
Previous studies have shown that components of the
endogenous digestive microflora can utilize oxalate, po-
tentially limiting its absorption from the intestinal lumen
[10]. Oxalobacter formigenes contains 2 enzymes [formyl
coA transferase (frc) and oxalyl-coenzyme A decarboxy-
lase (oxc)] that allow it to utilize oxalate as an energy
source, in the process converting it to formate and CO2,
as well as a specific oxalate/formate antiporter (OxlT)
[28]. Epidemiology suggests that colonization with O.
formigenes could be an important determinant of urinary
oxalate excretions [29, 30]. The lactic acid bacteria that
constitute Oxadrop have been shown not to contain the
OxlT gene [11]. Nevertheless, the bacteria in Oxadrop
can degrade small amounts of oxalate in vitro, and in a
small group of mildly hyperoxaluric stone formers, oral
administration of this preparation (1 packet daily) de-
creased urinary oxalate excretion by 40% after 1 month
(mean 55.5 mg to 33.5 mg/day, P < 0.05) [11]. Although
the mechanism by which Oxadrop reduced urinary ox-
alate excretion in this study is not clear, it could act via
many potential pathways, for example, by improving gas-
trointestinal barrier function and reducing paracellular
oxalate fluxes, directly degrading oxalate, or by changing
activity of oxalate transporters.
Although the percentage decrease in urinary oxalate
excretion was lower in our study than the previous one in
idiopathic calcium oxalate stone formers [10], the abso-
lute decrease was similar (e.g., 22 mg/day on 2 doses per
day; Table 1). Therefore, the metabolic capacity of the
collection of bacteria contained in Oxadrop could have
an upper limit, or reducing gastrointestinal oxalate ab-
sorption could be more difficult in patients with true en-
teric hyperoxaluria. These results also suggest that timing
of administration may be important. In the earlier study
by Campieri et al [10], the preparation was administered
twice daily before meals, whereas in ours it was admin-
istered once daily several hours after the major meal.
Our premise was that the preparation acted to colonize
the large intestine, and that timing of administration was
not an important variable. However, it is possible that
coadministration with food may be beneficial, and that
perhaps the bacteria can degrade oxalate in the intestine
during transit.
Lactic acid bacteria are currently classified as non-
pathogenic bacteria, which are permitted in food by the
Food and Drug Administration. A preparation slightly
different from Oxadrop (VSL#3) has recently been
shown to be safe and effective in the treatment of pouch-
itis, the major long-term complication after ileal pouch-
anal anastomosis for ulcerative colitis [12]. Caution may,
however, be required when these or similar probiotic
preparations are used in the very young with immature
immune systems [14] or immunocompromised patients
[31]. In addition to treatment of chronic gastrointestinal
inflammation associated with inflammatory bowel dis-
ease, preparations of lactobacilli have been successfully
used for treatment of acute infectious diarrhea [32].
Although the current results suggest that manipulation
of gastrointestinal flora in patients with enteric hyperox-
aluria using Oxadrop can influence oxalate absorption
and, hence, urinary oxalate excretion, the effect was rel-
atively small such that urinary supersaturation levels fell
but the change was not statistically significant. Further,
urinary oxalate rose on the highest Oxadrop dose, so
that there may be an optimal dose, and that it might be
possible to give too much of this probiotic. This observa-
tion underlines the importance of careful dosing studies.
All patients were asked to maintain a standard low ox-
alate diet; however, diet was not controlled in this study.
Oxalate absorption in enteric hyperoxaluria is likely to be
dependent on diet composition, and indeed in our paired
urine collections variability in 24-hour oxalate excretion
was 20.2 ± 14.9% (mean ± SD), compared to 12.5 ±
11.1% for creatinine. Therefore, in future trials, carefully
controlling the diet might decrease variability and im-
prove the ability to detect significant effects in smaller
patient populations such as this.
CONCLUSION
Hyperoxaluria is often a contributing factor to renal
stone formation, an extremely common and costly health
condition in the United States. Certain patients with
chronic gastrointestinal disease have more extreme hy-
peroxaluria that can result not only in stones, but renal
scarring and failure. In both groups of patients, increased
absorption of oxalate across the gastrointestinal tract is
likely pathogenic. Probiotics can improve gastrointesti-
nal health, and the current and previous [11] studies sug-
gest that such a strategy may decrease oxalate levels in
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the urine of hyperoxaluric individuals. If these results are
confirmed in a larger population of patients in a placebo-
controlled trial, longer-term treatment trials with stone-
forming rate as an outcome would be indicated.
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